scispace - formally typeset
C

C. Balana

Researcher at Complutense University of Madrid

Publications -  15
Citations -  778

C. Balana is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Temozolomide & Cancer. The author has an hindex of 10, co-authored 15 publications receiving 614 citations.

Papers
More filters
Journal ArticleDOI

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastian Moran, +35 more
- 01 Oct 2016 - 
TL;DR: The development of a DNA methylation based assay can significantly improve diagnoses of cancer of unknown primary and guide more precise therapies associated with better outcomes.
Journal Article

O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

C. Balana, +9 more
- 01 Apr 2003 - 
TL;DR: The methylation-specific PCR assay in serum DNA could be a good predictive tool for selecting GBM patients to be treated with BCNU or alternatively with the combination of temozolamide plus cisplatin, with a good correlation between serum and primary tumor tissue.
Journal ArticleDOI

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

Maxime Janin, +58 more
- 13 Aug 2019 - 
TL;DR: It is found that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine, which exhibits tumor-suppressor characteristics in vivo gliomas models and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress.
Journal ArticleDOI

Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study.

Salvador Villà, +11 more
- 02 Mar 2011 - 
TL;DR: The data suggest that the new Graded Prognostic Assessment (GPA) scale in a prospective validation study to compare it with two published prognostic indexes is a valid prognostic index.
Journal ArticleDOI

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

Miguel J. Gil, +14 more
- 01 Jul 2012 - 
TL;DR: Bvacizumab plus irinotecan in recurrent MG improves responses, progression-free survival, and OS compared with historical data.